Latest News & Features
Asia-Pacific
Companies in Australia will be able to continue to patent human genes after a court rejected an appeal by a breast cancer survivor. 8 September 2014
Americas
Magistrate judge Christopher Burke has recommended that the US District Court for the District of Delaware affirm a motion to dismiss a patent infringement case related to the patent eligibility of subject matter, as laid out in 35 USC §101. 5 September 2014
article
Our expert comment this month looks at personalised medicine, but more from a business point of view than a medical one. As LSIPR readers will know, personalised medicine is all about tailoring treatment to the individual, and that, of course, can be extremely complicated. 4 September 2014
Big Pharma
Law firm Simmons & Simmons has expanded its Düsseldorf office with the addition of a new partner. 3 September 2014
Big Pharma
English High Court Justice Philip James Sales has found a patent covering AstraZeneca’s bestselling drug Symbicort invalid after a challenge by Israeli generic drug maker Teva. 3 September 2014
Europe
WilmerHale has added life sciences lawyer and IP litigation specialist Anthony Trenton to its practice in London. 2 September 2014
Americas
Novartis’s generic arm Sandoz may not market a generic version of Maryland-based United Therapeutics’ Remodulin hypertension drug, the US District Court for the District of New Jersey ruled on Friday (August 29). 1 September 2014
Americas
The FDA has accepted applications by generic drug makers Mylan and Novartis subsidiary Sandoz for a three-times-weekly version of blockbuster drug Copaxone, it was announced yesterday. 29 August 2014
Big Pharma
Novartis Pharmaceuticals has launched a lawsuit against generics company Zydus Noveltech and its subsidiaries, accusing them of infringing patents relating to a drug used to treat Alzheimer’s and Parkinson’s disease. 28 August 2014
Americas
The US Court of Appeals for the Federal Circuit yesterday (August 21) upheld a lower court’s decision that a patent covering rheumatoid arthritis drug Humira (adalimumab) is invalid. 22 August 2014